论文部分内容阅读
目的探讨125Ⅰ粒子植入联合吉西他滨和顺铂化疗方案(GP)治疗中晚期肺鳞癌患者的临床疗效。方法选取2013年11月至2014年10月枣庄矿业集团中心医院收治的60例中晚期肺鳞癌患者作为研究对象,按随机数字表法将其分为试验组和对照组,各30例。对照组患者采用GP,试验组患者采用125Ⅰ粒子植入联合GP进行治疗,比较两组患者的近期疗效、无进展生存期(PFS)及不良反应发生情况。结果试验组患者的近期总有效率明显高于对照组,差异有统计学意义(P<0.05);试验组患者的中位PFS为(6.1±1.5)个月,明显长于对照组的(3.9±0.8)个月,差异有统计学意义(P<0.05)。结论 125Ⅰ粒子植入联合GP治疗中晚期肺鳞癌患者临床疗效明显,可明显提高患者的PFS,且不良反应少,是一种理想的治疗方法。
Objective To investigate the clinical efficacy of 125 Ⅰ particle implantation combined with gemcitabine and cisplatin chemotherapy (GP) in the treatment of advanced squamous cell carcinoma of the lung. Methods Sixty patients with advanced squamous cell carcinoma of lung squamous cell carcinoma admitted from Zaozhuang Mining Group Central Hospital from November 2013 to October 2014 were selected as study subjects and divided into experimental group and control group with 30 cases in each group according to random number table method. The patients in the control group were treated with GP, and the patients in the test group were treated with 125I seed implantation combined with GP. The short-term efficacy, progression-free survival (PFS) and adverse reactions were compared between the two groups. Results The total effective rate of the trial group was significantly higher than that of the control group (P <0.05). The median PFS of the trial group was (6.1 ± 1.5) months which was significantly longer than that of the control group (3.9 ± 0.8) months, the difference was statistically significant (P <0.05). Conclusion 125 Ⅰ particle implantation combined with GP in the treatment of advanced lung squamous cell carcinoma patients with significant clinical efficacy, can significantly improve the patient’s PFS, and fewer adverse reactions, is an ideal method of treatment.